CE Certification Etelcalcetide Injection: Quality Assured Product

Hybio Pharmaceutical Co., Ltd. is proud to introduce our latest product, Etelcalcetide Injection, which has been awarded the CE Certification. This injection is a novel calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis, Our Etelcalcetide Injection has undergone rigorous testing and has met the high standards required for CE Certification. This certification ensures that the product meets all relevant EU safety, health, and environmental protection requirements, making it a trusted choice for healthcare professionals and patients alike, With our commitment to quality and innovation, we are confident that our Etelcalcetide Injection will make a positive impact in the treatment of secondary hyperparathyroidism. It is our goal to provide safe and effective pharmaceutical products that improve the lives of patients and healthcare outcomes, We are excited to bring this advanced treatment option to the market and look forward to the positive impact it will have on the healthcare community